EI
NKTR icon

EAM Investors’s Nektar Therapeutics NKTR Stock Holding History

EAM Investors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-36,126
Closed -$2.6M – 351
2026
Q1 		$2.6M Buy
36,126
+23,154
+178% +$1.32M 0.3% 151
2025
Q4 		$548K Sell
12,972
-65,237
-83% -$3.65M 0.06% 255
2025
Q3 		$4.4M Buy
78,209
+54,053
+224% +$1.79M 0.5% 89
2025
Q2 		$624K Buy
+24,156
New +$271K 0.09% 199
2018
Q2 		– Sell
-4,270
Closed -$6.81M – 333
2018
Q1 		$6.81M Buy
4,270
+333
+8% +$429K 1.13% 1
2017
Q4 		$3.53M Sell
3,937
-2,777
-41% -$1.64M 0.63% 29
2017
Q3 		$2.42M Sell
6,714
-2,023
-23% -$633K 0.32% 127
2017
Q2 		$2.56M Sell
8,737
-631
-7% -$182K 0.42% 113
2017
Q1 		$3.3M Buy
+9,368
New +$2.11M 0.52% 58

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM Investors's NKTR Position: Q2 2026 in Review

EAM Investors sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 36,126 shares — an estimated $2.6M sold.

EAM Investors first reported a position in NKTR in Q1 2017 and held it in 9 quarters. The position peaked at $6.81M in Q1 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • EAM Investors reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EAM Investors sold 36,126 Nektar Therapeutics shares in Q2 2026, an estimated $2.6M.
  • EAM Investors first reported a position in Nektar Therapeutics in Q1 2017 and held it in 9 quarters.
  • EAM Investors's Nektar Therapeutics position peaked at $6.81M in Q1 2018.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.